With a market cap of $18.4 billion, Insulet Corporation (PODD) is a leading developer of innovative insulin delivery systems ...

Individuals transitioning from multiple daily injections to the Omnipod 5 system experienced an average HbA1c reduction of ...

Insulet announces the commercial launch of Omnipod 5 AID system in Australia, with Dexcom G6 and G7 CGM sensor compatibility.

Participants began with an average HbA1c level of 8.1%. After three months, people who used Omnipod 5 improved HbA1c by an ...

Insulet unveils positive RADIANT trial clinical data for its Omnipod 5 at the 18th international conference on ATTD.

A randomized study from Insulet of adults and children with Type 1 diabetes found that moving from multiple daily injections ...

Corporation shared new Omnipod 5 clinical data from its RADIANT study. Results from this multinational randomized controlled ...

Insulet Corporation PODD has witnessed strong momentum in the past year. Shares of the company have risen 62.9% compared with 9.9% growth of the industry during the same time frame. The S&P 500 ...

Insulet (PODD) announced its revolutionary Omnipod 5 Automated Insulin Delivery System is now available in Australia and will soon be offered ...

Insulet today announced that it's bringing its automated insulin delivery technology to a range of new geographies.

Picture: Pema Tamang Pakhrin Fast forward to today, and Pippa is competing at the City of Darwin NT Swimming Championships with a new tool helping her manage her condition — the Omnipod 5, Australia’s ...